Altered microRNA profiles in plasma exosomes from mesial temporal lobe epilepsy with hippocampal sclerosis

Shaofeng Yan1, Hua Zhang1, Wenyan Xie2

  • 1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Oncotarget
|December 8, 2016
PubMed

Insights

Exosomal microRNAs are altered in mesial temporal lobe epilepsy with hippocampal sclerosis (mTLE-HS). Specific microRNAs, like miR-8071, show diagnostic potential and may regulate seizure development in mTLE-HS.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Mesial temporal lobe epilepsy with hippocampal sclerosis (mTLE-HS) is the predominant form of focal epilepsy.
  • Understanding the molecular mechanisms, particularly involving microRNAs, is crucial for mTLE-HS.
  • Exosomes play a role in intercellular communication and disease pathogenesis.

Purpose of the Study:

  • To investigate the expression and functional roles of exosomal microRNAs in mTLE-HS.
  • To identify potential diagnostic biomarkers and therapeutic targets for mTLE-HS.

Main Methods:

  • Differential expression analysis of exosomal microRNAs in mTLE-HS patients versus healthy controls.
  • Validation of candidate microRNAs using quantitative methods.
  • Bioinformatic analysis to predict target genes and affected biological pathways.

Main Results:

  • 50 microRNAs were differentially expressed in mTLE-HS exosomes; 48 decreased, 2 increased.
  • Six candidate microRNAs (miR-3613-5p, miR-4668-5p, miR-8071, miR-197-5p, miR-4322, miR-6781-5p) were validated.
  • Bioinformatics revealed involvement in axon guidance, cancer pathways, cytoskeleton regulation, and signaling pathways (MAPK, PI3K-Akt).
  • miR-8071 demonstrated high diagnostic value (83.33% sensitivity, 96.67% specificity) and correlated with seizure severity.

Conclusions:

  • Exosomal microRNAs are significantly dysregulated in mTLE-HS.
  • These microRNAs may act as regulators of seizure development in mTLE-HS.
  • Exosomal microRNAs, particularly miR-8071, represent promising diagnostic biomarkers and potential therapeutic targets for mTLE-HS.